Public Comment
ASTRO posts drafts of clinical practice guidelines, white papers and other documents for public comment before they are finalized and sent to ASTRO's Board of Directors for approval. The public comment period is an integral part of guidance development and is preceded by a series of reviews and revisions and may be followed by a final peer review if the document is submitted to a journal for publication. ASTRO encourages those in the radiation oncology field to comment and then share with colleagues, producing a more robust public response.
ASTRO seeks public comments for updated guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer
ASTRO requests feedback on a draft guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer. The guideline covers a broad scope of patients with localized prostate cancer receiving external beam radiation therapy as primary local therapy, including patients with low-risk prostate cancer who decline active surveillance and those with intermediate-, high- or very high-risk prostate cancer. Please review the guideline and submit comments through the webform by Wednesday, March 25.
ASTRO seeks public comments for updated guideline on Radiation Therapy for Pancreatic Cancer
ASTRO requests feedback on a draft guideline on Radiation Therapy for Pancreatic Cancer. This guideline addresses radiation therapy for the treatment of patients with invasive ductal pancreatic adenocarcinoma with a broad spectrum of nonmetastatic (resectable, borderline resectable, locally advanced, and locoregionally recurrent) and metastatic pancreatic cancer. The scope focuses on radiation therapy delivered in the definitive, preoperative, postoperative and palliative settings. Please review the guideline and submit comments through the webform by Wednesday, April 15.
ASTRO requests feedback on a draft guideline on Hypofractionated Radiation Therapy for Localized Prostate Cancer. The guideline covers a broad scope of patients with localized prostate cancer receiving external beam radiation therapy as primary local therapy, including patients with low-risk prostate cancer who decline active surveillance and those with intermediate-, high- or very high-risk prostate cancer. Please review the guideline and submit comments through the webform by Wednesday, March 25.
ASTRO seeks public comments for updated guideline on Radiation Therapy for Pancreatic Cancer
ASTRO requests feedback on a draft guideline on Radiation Therapy for Pancreatic Cancer. This guideline addresses radiation therapy for the treatment of patients with invasive ductal pancreatic adenocarcinoma with a broad spectrum of nonmetastatic (resectable, borderline resectable, locally advanced, and locoregionally recurrent) and metastatic pancreatic cancer. The scope focuses on radiation therapy delivered in the definitive, preoperative, postoperative and palliative settings. Please review the guideline and submit comments through the webform by Wednesday, April 15.
